UA75896C2 - Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis - Google Patents

Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis Download PDF

Info

Publication number: UA75896C2
Authority: UA; Ukraine
Prior art keywords: layer; compositions; pseudoephedrine; coating; tablet
Prior art date: 2000-10-06

Application number

UA2003054060A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-06

Filing date

2001-09-28

Publication date

2006-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8170029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA75896(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-09-28 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2006-06-15 Publication of UA75896C2 publication Critical patent/UA75896C2/uk

Links

238000000034 method Methods 0.000 title abstract description 19
WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 title abstract description 10
229960003449 epinastine Drugs 0.000 title abstract description 9
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 title abstract description 8
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 title abstract description 7
229960003908 pseudoephedrine Drugs 0.000 title abstract description 7
239000008194 pharmaceutical composition Substances 0.000 title description 3
206010039085 Rhinitis allergic Diseases 0.000 title description 2
201000010105 allergic rhinitis Diseases 0.000 title description 2
239000000203 mixture Substances 0.000 abstract description 53
150000003839 salts Chemical class 0.000 abstract description 15
239000000546 pharmaceutical excipient Substances 0.000 abstract description 8
239000000739 antihistaminic agent Substances 0.000 abstract description 5
150000001875 compounds Chemical class 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
239000003937 drug carrier Substances 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
208000026935 allergic disease Diseases 0.000 abstract description 2
230000001387 anti-histamine Effects 0.000 abstract description 2
239000000850 decongestant Substances 0.000 abstract 1
239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 description 26
239000011248 coating agent Substances 0.000 description 25
238000004519 manufacturing process Methods 0.000 description 15
238000013270 controlled release Methods 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
239000008108 microcrystalline cellulose Substances 0.000 description 6
229940016286 microcrystalline cellulose Drugs 0.000 description 6
235000019813 microcrystalline cellulose Nutrition 0.000 description 6
239000000126 substance Substances 0.000 description 6
CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
229960004159 pseudoephedrine sulfate Drugs 0.000 description 5
239000000454 talc Substances 0.000 description 5
235000012222 talc Nutrition 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
230000000172 allergic effect Effects 0.000 description 4
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
229910052782 aluminium Inorganic materials 0.000 description 4
230000000181 anti-adherent effect Effects 0.000 description 4
229940125715 antihistaminic agent Drugs 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
239000003973 paint Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
-1 hydrochloric acid Chemical class 0.000 description 3
239000002966 varnish Substances 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
241001274613 Corvus frugilegus Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
235000019658 bitter taste Nutrition 0.000 description 2
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical group [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002388 eustachian tube Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
235000019691 monocalcium phosphate Nutrition 0.000 description 2
230000000510 mucolytic effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
241000755093 Gaidropsarus vulgaris Species 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
XKXPEVVVXXTWGR-UHFFFAOYSA-N [Na].[Na].[Na].C(=O)(O)C1(NN(C(=C1C1=CC=C(C=C1)S(=O)(=O)O)O)C1=CC=C(C=C1)S(=O)(=O)O)N=NC1=NNC=C1 Chemical compound [Na].[Na].[Na].C(=O)(O)C1(NN(C(=C1C1=CC=C(C=C1)S(=O)(=O)O)O)C1=CC=C(C=C1)S(=O)(=O)O)N=NC1=NNC=C1 XKXPEVVVXXTWGR-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
229960005174 ambroxol Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003870 bromhexine Drugs 0.000 description 1
OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229920003064 carboxyethyl cellulose Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
229940011411 erythrosine Drugs 0.000 description 1
235000012732 erythrosine Nutrition 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000010855 food raising agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
150000004291 polyenes Chemical class 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000009475 tablet pressing Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2003054060A 2000-10-06 2001-09-28 Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis UA75896C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00121828		2000-10-06
PCT/EP2001/011229 WO2002028373A1 (en)	2000-10-06	2001-09-28	New pharmaceutical compositions containing epinastine and pseudoephedrine

Publications (1)

Publication Number	Publication Date
UA75896C2 true UA75896C2 (en)	2006-06-15

Family

ID=8170029

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003054060A UA75896C2 (en)	2000-10-06	2001-09-28	Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis

Country Status (31)

Country	Link
EP (1)	EP1326586B1 (de)
JP (1)	JP2004521864A (de)
KR (1)	KR20030036894A (de)
CN (1)	CN1291715C (de)
AR (2)	AR032479A1 (de)
AT (1)	ATE424813T1 (de)
AU (2)	AU2002212290B2 (de)
BG (1)	BG107686A (de)
BR (1)	BR0114339A (de)
CA (1)	CA2423288C (de)
CZ (1)	CZ2003945A3 (de)
DE (1)	DE60137952D1 (de)
EA (1)	EA007288B1 (de)
EC (1)	ECSP034513A (de)
EE (1)	EE200300138A (de)
ES (1)	ES2323570T3 (de)
HR (1)	HRP20030259A2 (de)
HU (1)	HUP0300970A3 (de)
IL (1)	IL154884A0 (de)
ME (1)	MEP39708A (de)
MX (1)	MXPA03002900A (de)
MY (1)	MY131159A (de)
NO (1)	NO20031537L (de)
NZ (1)	NZ525653A (de)
PE (1)	PE20020324A1 (de)
PL (1)	PL366123A1 (de)
SK (1)	SK4052003A3 (de)
UA (1)	UA75896C2 (de)
WO (1)	WO2002028373A1 (de)
YU (1)	YU24603A (de)
ZA (1)	ZA200302079B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA03011705A (es) *	2001-06-20	2004-03-19	Schering Corp	Antihistaminas para el tratamiento de congestion nasal y obstruccion nasal.
JP4549618B2 (ja) *	2001-11-22	2010-09-22	第一三共ヘルスケア株式会社	鼻炎用組成物
BR0313175A (pt) *	2002-08-02	2005-06-14	Boehringer Ingelheim Int	Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina
JP5021155B2 (ja) *	2003-08-01	2012-09-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物
EP1750717B1 (de) *	2004-02-11	2017-07-19	Rubicon Research Private Limited	Pharmazeutische zusammensetzungen mit kontrollierter freisetzung und verbesserter bioverfügbarkeit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903151A1 (de) *	1997-09-22	1999-03-24	ASTA Medica Aktiengesellschaft	Verwendung von Kombinationen enthaltend nichtsedierende Antihistaminika und Alfa-Adrenergische Agonisten für die topische Behandlung von Rhinitis/Konjunktivitis sowie Erkältungs- und Grippe-Symptomen
PL193131B1 (pl) *	1997-12-23	2007-01-31	Schering Corp	Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
AU6252699A (en) *	1998-10-09	2000-05-01	Schering Corporation	Composition and method for treating allergic diseases
US6613357B2 (en) *	2000-01-13	2003-09-02	Osmotica Corp.	Osmotic device containing pseudoephedrine and an H1 antagonist

2001
- 2001-09-04 PE PE2001000883A patent/PE20020324A1/es not_active Application Discontinuation
- 2001-09-28 AT AT01980449T patent/ATE424813T1/de active
- 2001-09-28 WO PCT/EP2001/011229 patent/WO2002028373A1/en not_active Ceased
- 2001-09-28 DE DE60137952T patent/DE60137952D1/de not_active Expired - Lifetime
- 2001-09-28 UA UA2003054060A patent/UA75896C2/uk unknown
- 2001-09-28 SK SK405-2003A patent/SK4052003A3/sk unknown
- 2001-09-28 EP EP01980449A patent/EP1326586B1/de not_active Expired - Lifetime
- 2001-09-28 MX MXPA03002900A patent/MXPA03002900A/es active IP Right Grant
- 2001-09-28 HU HU0300970A patent/HUP0300970A3/hu unknown
- 2001-09-28 YU YU24603A patent/YU24603A/sh unknown
- 2001-09-28 AU AU2002212290A patent/AU2002212290B2/en not_active Ceased
- 2001-09-28 BR BR0114339-5A patent/BR0114339A/pt not_active Application Discontinuation
- 2001-09-28 NZ NZ525653A patent/NZ525653A/en unknown
- 2001-09-28 ES ES01980449T patent/ES2323570T3/es not_active Expired - Lifetime
- 2001-09-28 IL IL15488401A patent/IL154884A0/xx unknown
- 2001-09-28 JP JP2002531999A patent/JP2004521864A/ja active Pending
- 2001-09-28 EE EEP200300138A patent/EE200300138A/xx unknown
- 2001-09-28 EA EA200300430A patent/EA007288B1/ru not_active IP Right Cessation
- 2001-09-28 CN CNB018169376A patent/CN1291715C/zh not_active Expired - Lifetime
- 2001-09-28 AU AU1229002A patent/AU1229002A/xx active Pending
- 2001-09-28 ME MEP-397/08A patent/MEP39708A/xx unknown
- 2001-09-28 CA CA002423288A patent/CA2423288C/en not_active Expired - Lifetime
- 2001-09-28 KR KR10-2003-7004846A patent/KR20030036894A/ko not_active Ceased
- 2001-09-28 CZ CZ2003945A patent/CZ2003945A3/cs unknown
- 2001-09-28 HR HR20030259A patent/HRP20030259A2/hr not_active Application Discontinuation
- 2001-09-28 PL PL01366123A patent/PL366123A1/xx unknown
- 2001-10-04 MY MYPI20014635A patent/MY131159A/en unknown
- 2001-10-05 AR ARP010104692A patent/AR032479A1/es not_active Application Discontinuation
2003
- 2003-03-13 EC EC2003004513A patent/ECSP034513A/es unknown
- 2003-03-14 ZA ZA200302079A patent/ZA200302079B/en unknown
- 2003-03-28 BG BG107686A patent/BG107686A/bg unknown
- 2003-04-04 NO NO20031537A patent/NO20031537L/no not_active Application Discontinuation
2012
- 2012-07-19 AR ARP120102612A patent/AR087240A2/es unknown

Also Published As

Publication number	Publication date
AR087240A2 (es)	2014-03-12
EA200300430A1 (ru)	2003-10-30
AR032479A1 (es)	2003-11-12
CA2423288A1 (en)	2002-04-11
HUP0300970A3 (en)	2005-03-29
HUP0300970A2 (hu)	2003-11-28
HK1062196A1 (en)	2004-10-21
ZA200302079B (en)	2004-05-05
PE20020324A1 (es)	2002-06-18
CA2423288C (en)	2007-11-13
EP1326586B1 (de)	2009-03-11
AU1229002A (en)	2002-04-15
ES2323570T3 (es)	2009-07-21
CN1468094A (zh)	2004-01-14
NO20031537L (no)	2003-06-04
YU24603A (sh)	2006-05-25
HRP20030259A2 (en)	2005-02-28
MXPA03002900A (es)	2003-09-10
CZ2003945A3 (cs)	2003-08-13
WO2002028373A1 (en)	2002-04-11
EE200300138A (et)	2003-08-15
PL366123A1 (en)	2005-01-24
ECSP034513A (es)	2003-04-25
MEP39708A (en)	2011-02-10
EP1326586A1 (de)	2003-07-16
KR20030036894A (ko)	2003-05-09
BG107686A (bg)	2003-11-28
IL154884A0 (en)	2003-10-31
ATE424813T1 (de)	2009-03-15
SK4052003A3 (en)	2003-09-11
NZ525653A (en)	2006-07-28
NO20031537D0 (no)	2003-04-04
EA007288B1 (ru)	2006-08-25
JP2004521864A (ja)	2004-07-22
DE60137952D1 (de)	2009-04-23
AU2002212290B2 (en)	2006-08-03
MY131159A (en)	2007-07-31
BR0114339A (pt)	2003-12-09
CN1291715C (zh)	2006-12-27

Publication	Publication Date	Title
AU2021202009B2 (en)	2023-04-13	Pharmaceutical formulations comprising tenofovir and emtricitabine
RU2616516C2 (ru)	2017-04-17	Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
TWI314868B (en)	2009-09-21	Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient
AU2003229705C1 (en)	2017-09-07	High drug load tablet
ES2437072T5 (es)	2021-10-13	Preparación sólida
EP2540318B1 (de)	2018-10-24	Feststoffpräparat mit verzögerter freisetzung zur oralen verabreichung
JP7592001B2 (ja)	2024-11-29	エフロルニチンとスリンダクの固定用量複合製剤
US10842759B2 (en)	2020-11-24	Pharmaceutical compositions for N-propargylamine derivative
CN117503775A (zh)	2024-02-06	治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
JPS5883618A (ja)	1983-05-19	ニトロフラントイン投与剤
US20230225977A1 (en)	2023-07-20	Formulation comprising daprodustat
UA75896C2 (en)	2006-06-15	Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis
WO2021080529A1 (en)	2021-04-29	Solid pharmaceutical formulations comprising ticagrelor
US8835495B2 (en)	2014-09-16	Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association
MXPA06003479A (es)	2006-06-08	Una composicion farmaceutica de liberacion prolongada y un proceso para su preparacion.
WO2018028841A1 (en)	2018-02-15	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017029226A1 (en)	2017-02-23	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2021117697A1 (ja)	2021-06-17	固形製剤
TWI810656B (zh)	2023-08-01	二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
Patil	2021	A Review: A new trend in drug delivery Oro-dispersible tablets
Shah et al.	2011	Formulation and Development of Fast Disintegrating Tablets Using Ranitidine HCL as a Model Drug
TW202513072A (zh)	2025-04-01	比替拉韋及利那卡帕韋之醫藥配方
AU2007201830C1 (en)	2017-09-07	High drug load tablet
Lokesha	2012	Design and In-Vitro Evaluation of Fast Disintegrating Tablets of an Antihypertensive Drug
Kanani et al.	2011	Ars Pharmaceutica